ProMedEx (Professional Medical Expertise)بروميديكس
- Price
- 84.30 SAR
- ROE
- 27.8%
- Net margin
- 10.0%
Current price84.3SAR
Not enough data to compute a fair value yet. Add the latest annual financials in the Hajras backend.
Health Check
63.8
Overall / 100
Good (66+)Caution (40–65)Risk (<40)
Rewards
- Strong return on equity (27.8%).
- Above-average growth expected.
Risks
- Stretched balance sheet / elevated debt.
- Low fair-value confidence — methods disagree or data is thin.
Scores are computed automatically from the real financial statements (Value from fair value; the rest from growth, profitability, balance sheet and dividends). A decision aid, not investment advice.
Price, corporate actions & news
Demo series
D — DividendS — Split▲ good · ▼ bad newstap a marker for detailsDemo series
Growth & profitability
Revenue, net income and margin.
RevenueNet incomeNet margin %tap a bar for figures
Key figures
Covers 4 years · FY2022–FY2025
| Metric | FY'22 | FY'23 | FY'24 | FY'25 |
|---|---|---|---|---|
| Revenue | 176.05M | 250.12M | 313.17M | 418.78M |
| Net Income | 19.02M | 24.84M | 27.65M | 41.71M |
| Net Margin | 10.8% | 9.9% | 8.8% | 10.0% |
| Operating Cash Flow | -3.92M | 5.88M | -1.88M | 715.3K |
| OCF Margin | -2.2% | 2.4% | -0.6% | 0.2% |
| Capital Expenditure | 6.51M | 8.98M | 6.58M | 24.23M |
| Free Cash Flow | -10.43M | -3.10M | -8.46M | -23.52M |
| FCF Margin | -5.9% | -1.2% | -2.7% | -5.6% |
| FCF Conversion | -54.9% | -12.5% | -30.6% | -56.4% |
| EPS (Diluted) | — | — | — | — |
| Dividend / Share | — | — | — | — |
Dividend return (if you buy today)
This company doesn’t currently pay a dividend, so there’s no income return to project. The fair-value gauge above covers the price side.
Dividend history
Dividend / share & historical yield (SAR).
No dividend history — this company doesn’t currently pay a dividend.
Valuation breakdown
Fair value = median of the applicable methods.
Each method below is a different lens on the same company — no single method dominates the result.
Discounted Cash Flow
Excluded — non-positive free cash flow
N/A
Dividend Discount Model
Excluded — company pays no dividend
N/A
Graham Number
Excluded — EPS ≤ 0
N/A
Residual Income (justified P/B)
Excluded — needs positive book value
N/A
Earnings Power Value
Excluded — non-positive normalized earnings
N/A
DCF only is anchored on FY2025 — the latest year with positive cash flow that supports a value. The other methods (DDM, Graham, RIM, EPV) use current / normalized figures.
Fair Value (median)—
▸ Show assumptions▾ Assumptions
- Effective discount rate
- 6.00%
- CAPM cost of equity
- 10.50%
- Risk-free rate
- 4.50%
- Equity risk premium
- 6.00%
- DCF growth (stage 1)
- 8.00%
- DCF terminal growth
- 3.00%
- DCF forecast years
- 5
- DDM dividend growth
- 3.00%
Tune these per company in the Hajras Odoo backend; values recompute automatically.
Wealth simulator
What if you'd invested in ProMedEx (Professional Medical Expertise) regularly?
Starting year
Not enough history to simulate.
Community Notes0
No notes yet. Be the first to share a thesis.